anxiety – Page 2 – mycolab.ai

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

mycolabadmin

This study surveyed 2,800 Canadians about their views on using psilocybin (a psychedelic compound from certain mushrooms) to help patients with terminal illnesses manage existential distress and anxiety. About 79% of respondents thought it was a reasonable medical option, and 85% believed the government should cover the costs. People who had previous experience with psilocybin, those exposed to palliative care, and those with progressive political views were most supportive of this therapy.

Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences

mycolabadmin

People who use psychedelic substances like psilocybin or LSD sometimes experience profound changes in how they understand reality that can be distressing and last for months or years. This study interviewed 26 people who went through such difficult experiences and found that what helped them most was practicing grounding techniques (like yoga, spending time in nature, and creative activities), talking about their experiences with others, and learning to accept their new perspectives. The research shows that while these experiences can be challenging, people can recover and grow from them with the right support and practices.

Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms

mycolabadmin

Psilocybin mushrooms show promise as a treatment for obsessive-compulsive disorder (OCD), a condition where people experience unwanted intrusive thoughts and compulsive behaviors. Current standard treatments with antidepressants don’t work for many patients and take weeks to show effects. Early research suggests psilocybin may reduce OCD symptoms quickly and works in treatment-resistant cases, though more rigorous studies are needed to confirm its effectiveness and understand how it works in the brain.

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects

mycolabadmin

This study examined whether taking the antidepressant escitalopram before using psilocybin affects the drug’s effects. Twenty-three healthy participants took either escitalopram or placebo for two weeks, then received a dose of psilocybin. Surprisingly, escitalopram did not reduce the positive mood effects of psilocybin and actually reduced some negative side effects like anxiety and bad feelings. The combination appeared safe with no increased cardiovascular risks.

Associations between psychedelic-related and meditation-related variables: A longitudinal study

mycolabadmin

This study of over 13,000 people examined how using psychedelics relates to meditation practices. Researchers found that people who used psychedelics during the study period increased their meditation practice more than those who didn’t. Importantly, people who already had higher levels of mindfulness and self-compassion before using psychedelics had less difficult experiences during their use. However, among people who were already meditating regularly, psychedelic use was linked to more difficulties during meditation.

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

Olive mill solid waste induces beneficial mushroom-specialized metabolite diversity revealed by computational metabolomics strategies

mycolabadmin

This study shows how adding olive mill waste to mushroom growing substrate can increase beneficial compounds in mushrooms while reducing harmful toxins. Researchers grew two types of edible mushrooms (lion’s mane and king oyster) on substrate containing different amounts of olive mill waste and used advanced chemical analysis to identify how the waste affected the mushrooms’ medicinal compounds. Adding olive mill waste increased healthy compounds like hericenones and erinacerins while decreasing toxic enniatin compounds, potentially creating safer and more nutritious mushrooms for consumers.

Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report

mycolabadmin

A 41-year-old woman with Long-COVID experienced severe symptoms including fatigue, depression, anxiety, headaches, and brain fog that didn’t improve with traditional treatments. She decided to try psilocybin mushrooms and MDMA with guidance from a therapist. After multiple dosing sessions over several months, she reported roughly 80-90% improvement in her symptoms and was able to return to work and resume her studies. While this single case is promising, more research is needed to determine whether these psychedelics are truly safe and effective for Long-COVID.

Social pain: A systematic review on interventions

mycolabadmin

This study reviews different treatments for social pain—the emotional hurt from rejection and social exclusion. Researchers found that regular pain reliever acetaminophen, mindfulness meditation, and the psychedelic compound psilocybin can reduce social pain, while placebo pills also help when people believe they work. Interestingly, combining acetaminophen with forgiveness works better than either alone, suggesting that both physical and emotional pain may use similar brain pathways.

Gut-Brain Axis in Obesity: How Dietary Patterns Influence Psychological Well-Being and Metabolic Health

mycolabadmin

This review explains how our diet affects both our gut bacteria and our mental health through the gut-brain axis, a communication system between our digestive system and brain. Mediterranean diets rich in fiber and healthy foods support beneficial bacteria and mental well-being, while Western diets high in processed foods harm gut health and increase obesity risk. Emotional eating driven by stress and depression worsens obesity, but targeted dietary interventions with prebiotics, probiotics, and fiber can help restore balance and improve both physical and mental health.

Disease: anxiety